Equities

Mevis Medical Solutions AG

Mevis Medical Solutions AG

Actions
  • Price (EUR)24.30
  • Today's Change-0.10 / -0.41%
  • Shares traded20.00
  • 1 Year change-3.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Mevis Medical Solutions AG's revenues fell -7.57% from 18.76m to 17.34m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 7.79m to 4.92m, a -36.84% decrease.
Gross margin97.24%
Net profit margin32.60%
Operating margin26.74%
Return on assets23.24%
Return on equity32.27%
Return on investment28.00%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Mevis Medical Solutions AG fell by 1.58m. However, the company earned 5.85m from its operations for a Cash Flow Margin of 33.76%. In addition the company generated 989.98k cash from investing, though they paid out 7.79m more in financing than they received.
Cash flow per share3.22
Price/Cash flow per share7.57
Book value per share9.79
Tangible book value per share9.79
More ▼

Balance sheet in EURView more

Mevis Medical Solutions AG uses little or no debt in its capital structure.
Current ratio1.80
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)3.03%
Div growth rate (5 year)0.00%
Payout ratio (TTM)30.06%
EPS growth(5 years)-8.38
EPS (TTM) vs
TTM 1 year ago
-7.19
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.